Safety and efficacy of Setarud (IMOD™) among people living with HIV/AIDS: A review

Recent Patents on Anti-Infective Drug Discovery

Volumn 7, Issue 1, 2012, Pages 66-72

  Paydary, Koosha ^a   Emamzadeh Fard, Sahra ^a   Khorshid, Hamid Reza Khorram ^b   Kamali, Koorosh ^c   SeyedAlinaghi, SeyedAhmad ^a   Mohraz, Minoo ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^c UNIVERSITY OF ZANJAN   (Iran)

Author keywords

AIDS; Efficacy; HIV; Immunomodulator; IMOD ; Safety; Setarud

Indexed keywords

16ALPHA BROMOEPIANDROSTERONE; ANTIRETROVIRUS AGENT; CALANOLIDE A; CAROTENE; CROTON LECHLERI EXTRACT; CYCLOSPORIN A; DARUNAVIR; DEXAMETHASONE; ELVUCITABINE; ETRAVIRINE; FLAVONOID; GALACTOLIPID; HERBACEOUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOMODULATING AGENT; IMOD; INFLIXIMAB; IR 103; MARAVIROC; PLANT EXTRACT; RECOMBINANT INTERLEUKIN 2; ROSA CANINA EXTRACT; SELENIUM; SETARUD; TANACETUM VULGARE EXTRACT; TIPRANAVIR; UNCLASSIFIED DRUG; URTICA DIOICA EXTRACT; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; CARCINOGENICITY; CROTON LECHLERI; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; EMBRYOTOXICITY; ENTERITIS; GASTRITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNOMODULATION; INSULIN RESISTANCE; IRAN; LACTIC ACIDOSIS; LD 50; LIPODYSTROPHY; LIVER TOXICITY; MEDICINAL PLANT; MUTAGENICITY; NAUSEA; NONHUMAN; PANCREATITIS; PHLEBITIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; ROSA CANINA; SIDE EFFECT; SWEATING; UNSPECIFIED SIDE EFFECT; VERTIGO; WEIGHT REDUCTION;

ANIMALS; HIV; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; PLANT EXTRACTS; PLANT PREPARATIONS;

EID: 84858314965     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489112799829756     Document Type: Review

References (54)

1. Amon JJ. Dangerous medicines: Unproven AIDS cures and counterfeit anti-retroviral drugs. Global Health 2008; 4:5.
2. Fellay J, Boubakr K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with anti-retroviral treatment: Swiss HIV cohort study. Lancet 2001; 358:1322-27.
3. Keiser O, Fellay J, Opravil M, Hirsch HH, Hirschel B, Bernasconi E, et al. Adverse events to anti-retrovirals in the Swiss HIV cohort study: Effect in mortality and treatment modification. Antiviral therapy 2007; 12:1157-64.
4. Murphay RA, Sunpath H, Kuritzkes DR, Venter F, Gadhi RT. Anti-retroviral-therapy-associated toxicities in the resource poor world: the challenges of a limited formulary. J Inf Dis 2007; 196: S449-56.
5. th Conference on retroviruses and opportunistic infections. Boston, USA (2005).
6. th conference on retroviruses and opportunistic infections. Boston, USA (2005).
7. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Loui M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16: 1511-9.
8. Yalda A, Alinaghi SA, Hajiabdolbaghi M. Adherence to antiretroviral therapy and its determinants in AIDS patients. Tehran Univ Med J 2008; 66 (7): 445-447.
9. Beck E, Miners A, Tolley K. The cost of HIV treatment and care; a global review. Pharmacoeconomics 2001; 19:13-39.
10. th conference on retroviruses and opportunistic infections. San Fransisco, USA (2004).
11. rd ICAAC) Chicago, IL, 2003; Abstract H-875: 14-17 September.
12. Gazzard B, Poznik A, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, et al. An open-label assessment of TMC 125-a ne, next generation NNRTI, for 7 days in HIV-infected individuals with NNRTI resistance. AIDS 2003; 17:49-54.
13. th Conf Retroviruses Opportunist Inf. Boston, USA (2005).
14. Walmsley S, Leith J, Katlama C, Arasteh K, Pierone G, Blick G, et al. Pharmacokinetics and safety of tipranavir/ritonavir alone or in combination with saquinavir, amprenavir or lopinavir: interim analysis of BI1182, program and abstracts of the XV international AIDS conference, Bangkok, Thailand 2004, Abstract WeOrB1236:11-16 July.
15. Greene KB, Berger J, Reeves C, Moffat A, Standish LJ, Calabrese C. Most frequently used alternative and complementary therapies and activities by participants in the AMOCA study. J Assoc Nurs AIDS Care 1999; 10: 60-73.
16. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, et al. Effect of St. John's Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290:1500-4.
17. th Conf Retrovirus Opportunist Inf, San Francisco, CA: 30 January-2 February 2000.
18. Holodniy M, Koch J, Mistal M, Schmidt JA, Khandwala A, Pennington JE, et al. A double-blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol 1999; 94:3267-73.
19. Hunt PW, Deeks SG. Immune-based therapy for HIV infection: Are acute and chronic HIV infection different diseases? J Inf Dis 2006; 194:1632-4.
20. Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109: 681-8.
21. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79: 14169-78.
22. Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs JA, Polis MA, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004; 103: 3282-6.
23. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, et al. ANRS 079 Study Group. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial. AIDS 2003; 17: 343-51.
24. Mark P, Agatha O, Nesrina I, Gareth H, Frances G, Neil A. Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine. AIDS 2007; 21: 375-7.
25. Fernández-Cruz E, Navarro J, Gil J, Moreno S, González-Lahoz J, Carbone J. The potential role of the HIV-1 immunogen (Remune®) as a therapeutic vaccine in the treatment of HIV infection. Expert Rev Vaccines 2003; 2: 739-52.
26. Imami N, Westrop S, Cranage A, Burton C, Gotch F. Combined use of cytokines, hormones and therapeutic vaccines during effective antiretroviral therapy. Future HIV therapy 2007; 1: 171-9.
27. Novitsky, Y., Madani, H., Gharibdoust, F., Farhadi, M., Farzamfar, B., Mohraz, M. Use of a combination of Ethanolic rosa sp., Urtica dioica and Tanacetum vulgare extracts, further comprising selenium and urea and having been exposed to a pulsed electro-magnetic field, for the preparation of a medicament for immunostimulation and/or treatment of hiv infections. WO2007087825 (2007).
28. Kanter M, Coskun O, Budancamanak M. Hepatoprotective effects of Nigella sativa L and Urtica dioica L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloridetreated rats. World J Gastroenterol 2005; 11: 6684-8.
29. Schinella GR, Giner RM, Mordujovich BP, Rhos JL. Antiinflammatory effects of South American Tanacetum vulgare. J Pharm Pharmacol 1998; 50: 1069-74.
30. Ninomiya K, Matsuda H, Kubo M, Morikawa T, Nishida N, Yoshikawa M. Potent anti-obese principle from Rosa canina: Structural requirements and mode of action of trans-tiliroside. Bioorg Med Chem Lett 2007; 17: 3059-64.
31. Chrubasik JE, Roufogalis BD, Wagner H, Chrubasik S. A comprehensive review on the stinging nettle effect and efficacy profiles. Phytomedicine 2007; 14: 568-79.
32. Balzarini J, Neyts J, Schols D, Hosoya M, Van Damme E, Peumans W, et al. The mannosespecific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (Nacetylglucosamine) nspecific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res 1992; 18: 191-207.
33. Chiasson H, Belanger A, Bostanian N, Vincent C, Poliquin A. Acaricidal properties of Artemisia absinthium and Tanacetum vulgare (Asteraceae) essential oils obtained by three methods of extraction. J Econ Entomol 2001; 94: 167-71.
34. Dubois B, Peumans WJ, Van Damme EJ, Van Damme J, Opdenakker G. Regulation of gelatinase b (mmp-9) in leukocytes by plant lectins. Febs Lett 1998; 427: 275-8.
35. Rayman M. The importance of selenium to human health. Lancet 2000; 356: 233-41.
36. Whanger PD. Selenocompounds in plants and animals and their biological significance. J Amer Coll Nutr 2002; 21: 223-32.
37. Baghaei A, Esmaily H, Abdolghaffari AH, Baeeri M, Gharibdoost F, Abdollahi M. Efficacy of Setarud, a novel drug with potent antitoxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab. Indian J Biochem Biophyisics 2010; 47: 219-26.
38. Ángel, LA, Solomon H, Juan-Badaturuge M, Caroline J, Francisco P. In vitro anti HSV-1 and HSV-2 activity of Tanacetum vulgare extracts and isolated compounds: An approach to their mechanisms of action. Phytotherap Res 2011; 25(2): 296-301.
39. Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of the potential herbal sources of future drugs effective in oxidantrelated diseases. Inflamm Allerg Drug Targets 2009; 8: 2-10.
40. Bitiren M, Musa D, Ozgonul A, Ozaslan M, Kocyigit A, Sogut O, et al. Protetctive effects of green tea (Camelia sinensis), Hypericum perforatum and Urtica dioica on hepatic injury and lymphocytic DNA damage induced by carbon tetrachloride in wistar rats. Int J Pharmacol 2010; 6: 241-8.
41. Mohseni-salehi-monfared S, Habibollahzadeh E, Sadeghi H, Baeeri M, Abdollahi M. Efficacy of Setarud, a novel electromagneticallytreated multiherbal compound in mouse immunogenic type-1 diabetes. Arch Med Sci 2010; 6: 663-9.
42. Rezvanfar MA, Ahmadi A, Baeeri H, Abdollahi M. Inhibition of TNF-alpha and nitrosative/ oxidative stress by Setarud; a molecular mechanism of protection against letrozole-induced polycystic ovary. Toxicol Lett 2011; 205: S246.
43. Shirazi GF, Raoufi A, Yousefi M, Asgarian-Omran H, Memarian A, Khoshnoodi J, et al. In vitro immunoinhibitory effects of Setarud on human B lymphocyte. J Med Plants Res 2011; 5(11): 2223-31.
44. th [Epub ahead of print]. Azonov JA, KhorramKhorshid HR, Novitsky YA, Farhadi M, Ghorbanoghli
45. Shahhosseiny MH. Protective effects of setarud (IMOD™) on development of diet-inducedhypercholesterolemia in rabbits. DARU 2008; 16(4): 218-22.
46. KhorramKhorshid HR, Novitsky YA, Abdollahi M, Shahhosseiny MH, Sadeghi B, Madani H, et al. Studies on potential mutagenic and genotoxic activity of Setarud. DARU 2008; 16 (4): 223-8.
47. Khairandish P, Mohraz M, Farzamfar B, Abdollahi M, Shahhosseiny MH, Madani H, et al. Preclinical and phase 1 clinical safety of Setarud (IMOD™), a novel immunomodulator. DARU 2009: 17(3): 148-56.
48. Mohraz M, Khairandish P, Kazerooni PA, Davarpanah MA, Shahhosseiny MH, Mahdavian B, et al. A clinical trial on the efficacy of IMOD™ in AIDS patients. DARU 2009; 17(4): 277-84.
49. Mohraz M, Sedaghat A, SeyedAlinaghi SA, Asheri H, Mohammaddoust S, Gharibdoost F, et al. Post marketing surveillance on safety and efficacy of IMOD™ in Iranian patients with HIV/AIDS. Acta Medica Iranica 2011 (under review).
50. Mohammadirad A, Khorram-khorshid HR, Gharibdoost F, Abdollahi M. Setarud (IMOD™) as a multiherbal drug with promising benefits in animal and human studies. Asian J Animal Veterinary Advan 2011; 6(12): 1185-1192.
51. Agha-hosseini F, Mirzai-dizgah I, Adollahi M, Akbari-Gillani M. Efficacy of IMOD™ in the treatment of oral lichen planus. Open J Stomatol 2011; 1:13-7.
52. Mohammadpoor A, Eslami K, Mojtahedzadeh M, Najafi A, Ahmadi A, Dehnadi-Moghadam A, et al. Examination of Setarud in the management of patients with severe sepsis. DARU 2010; 18: 23-8.
53. SeyedAlinaghi SA, Payvarmehr F, Bayanolhagh S, Mohammadoust S, Mohraz M. Wart lesion in a patient associated with HIV infection treatment under IMOD™ therapy. Acta Medica Iranica 2011; 49: 6: 399-401.
54. Gouya MM. National Report on HIV and AIDS Cases. Tehran, Iran: Disease Management Center, Ministry of Health and Medical Education, 2011.